All Clinical Trials

SOURCE Lung

Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours

• Patients with early stage non-small cell lung cancer (NSCLC) or with a single oligometastatic lesion in the lung which cannot be treated with surgery and are suitable to receive high dose radiation therapy known as SABR.
• To be suitable for the study the patient must have a lesion which is located centrally within the lungs, near to the windpipe, heart or the major blood vessels near the heart.

• St. Luke’s Radiation Oncology Network.
• The Beacon Hospital

This study is investigating the safety of delivering SABR treatment to ultracentral lung tumours. An ultracentral lung tumour is a tumour that is positioned near the windpipe, heart or the major blood vessels near the heart. These tumours are more challenging for us to treat because they are near such important organs which we want to protect. The SOURCE study is investigating the safety of treating these tumours with high-dose precise radiotherapy called Stereotactic Ablative Radiation Therapy. (SABR)

TAORMINA

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA)

• Adults with breast cancer that has spread to five or fewer areas in one or two organs, who are well enough for systemic therapy and radiotherapy and have no widespread progression of disease.
• Eligibility is confirmed by tests and scans.

• St. Luke’s Radiation Oncology Network
• Bons UPMC, Cork

This study is looking at whether treating the 1-5 tumours which have spread from the breast with a special type of precise, high-dose radiation treatment, called stereotactic ablative radiotherapy (SABR),can help people live longer or do better overall.

In simpler terms, the trial is testing if using SABR, which targets and destroys cancer spots with very focused radiation while sparing healthy tissue, can improve results when added to regular treatments such as chemotherapy, hormone therapy, or targeted therapy.

ATNEC

Axillary management in cT1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy

• People aged 18 or older who were diagnosed with early-stage breast cancer that had spread to the lymph nodes in the armpit can take part if, after receiving chemotherapy before surgery (called neo-adjuvant chemotherapy), their breast surgery and sentinel lymph node biopsy show no remaining cancer cells in the armpit lymph nodes.
• In simpler terms, this means you may be eligible if your breast cancer originally involved the armpit lymph nodes, but chemotherapy successfully cleared the cancer from those nodes before surgery.

• University Hospital Galway
• St. Luke’s Radiation Oncology Network
• Beaumont Hospital
• St. James’s Hospital
• St. Vincent’s Hospital

This study is trying to find out whether patients with no remaining cancer in their lymph glands following chemotherapy given before surgery (called neoadjuvant chemotherapy) can safely avoid radiotherapy to the armpit following their surgery.

If the study shows that chemotherapy alone works just as well, then some patients may be able to avoid radiotherapy to the armpit, helping to reduce unnecessary treatment and lower the risk of long-term side effects.

E²-RADIatE Registry Study 

EORTC–ESTRO Radiotherapy Registry Study (OligoCare & ReCare Cohorts)

OligoCare Cohort: Patients with oligometastatic breast, prostate, colorectal, or lung cancer (typically ≤5 metastases) receiving curative-intent radiotherapy.

ReCare Cohort: Patients receiving high-dose re-irradiation to an area previously treated with radiation as part of standard care.

• St. Luke’s Radiation Oncology Network
• Beacon Hospital
• University Hospital Galway

The study aims to understand how radiotherapy is delivered in real-world settings, who receives it, what the short- and long-term outcomes are, and how treatment safety and effectiveness can be improved for future patients.

Spine SABR

Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases (CTRIAL-IE 20-03)

• Adults (18+) with one spinal tumour that has spread from another part of the body (oligometastatic or oligoprogressive cancer).
• The tumour must be considered suitable for SABR by the study team.

• St. Luke’s Radiation Oncology Network
• The Beacon Hospital

The study aims to find the highest safe SABR radiation dose that can effectively treat spinal tumours while protecting the spinal cord and surrounding organs. Once the maximum safe dose is identified, 88 patients will be treated at that level to confirm safety and effectiveness.

DP-IMRT Pancreas Trial:

Phase I/II study of dose-escalated hypofractionated Dose-Painted Intensity Modulated Radiotherapy.

• Adults with resectable or borderline resectable pancreatic adenocarcinoma who are fit to receive chemotherapy and radiotherapy, and have no evidence of cancer spread outside the pancreas (confirmed by CT/MRI/PET scans).
• Eligibility is confirmed through screening by the medical team.

• St. Luke’s Radiation Oncology Network

The study aims to find out whether dose-painted intensity modulated radiotherapy (DP-IMRT) , which allows higher, more focused radiation to the tumour while protecting healthy organs, can safely improve tumour control and surgical outcomes in pancreatic cancer.

NRG HN009

Randomised Phase II/III Trial of Radiation with High-dose cisplatin (100mg/m2) every three weeks versus radiation with low-dose weekly cisplatin (40mg/m2) for patients with locoregionally advanced squamous cell carcinoma of the head and neck.

• People who have been diagnosed with squamous cell head and neck cancer (SCCHN) and if you are eligible to receive high-dose concurrent chemo-radiation with cisplatin.
• The study doctor will decide eligibility based on screening tests such as blood tests.

• University Hospital Galway

The trial is testing the safety of two standardly used regimens of chemotherapy for head and neck cancer patients.

NRG GU012 SAMURAI Renal

• Adults (18+) with a kidney (renal cell) cancer which has spread beyond the kidneys.
• Patients must be suitable to receive standard of care immunotherapy and they can have started the immunotherapy up to 90 days before starting the trial radiotherapy.

• St. Luke’s Radiation Oncology Network (SLRON)
• Beacon Hospital

This study is testing whether adding stereotactic ablative radiotherapy (SABR), a very precise, high-dose form of radiation, to the main kidney tumor, along with immunotherapy, can help people with kidney cancer that has spread (metastatic renal cell carcinoma) do better than with immunotherapy alone. The tumors have not been removed with surgery.

Micro-GI Feasibility

A randomised controlled feasibility study assessing the feasibility of a probiotic-use and dietary counselling intervention for endometrial cancer patients receiving pelvic radiation therapy.

• People with endometrial cancer who are planned to receive external-beam radiotherapy as part of their cancer treatment.
• Patients must be suitable to receive probiotics as part of the study.

• St. Luke’s Radiation Oncology Network

This study is looking at whether probiotics (helpful bacteria) and specific dietary advice can help reduce side effects to the gut (bowel) that are sometimes caused by radiotherapy.

Sparekid:

Multi-marker risk assessment of kidney sensitivity to injury to personalise prevention of acute kidney injury (SPAREKID) – Cancer Chemotherapy

• People who are receiving certain chemotherapy drugs that can affect the kidneys such as cisplatin, carboplatin, oxaliplatin, or methotrexate.
• Patients must not have severely reduced kidney function, be on dialysis or have acute kidney injury at the time of joining the study.

• St. Luke’s Radiation Oncology Network
• The Mater Hospital

This is an observational study which aims to identify a test that will help doctors to know which patients are likely to have a kideny injury as a result of chemotherapy in the future.

SIMPLIFY-SABR-COMET

Single vs. Multiple fraction non-Inferiority trial of Stereotactic Ablative Radiotherapy for the Comprehensive treatment of Oligo-metastases/progression

• People who have one to five oligometastatic or oligo-progressive lesions (this means lesions which have spread from another part of the body).
• People who are considered suitable to receive SABR (this is decided by your radiation oncologist)

• Cork University Hospital
• Saint Luke’s Radiation Oncology Network
• Whitfield Hospital
• Bons UPMC, Cork
• The Beacon Hospital
• University Hospital Galway

The trial is determining what the side effects of single or multiple fraction Stereotactic Ablative Radiotherapy (SABR) for oligometastatic/progressive tumours are, and what is the most optimal treatment regime.